Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The first approvals of RSV vaccines (RSVpreF and RSVpreF3) targeted at infants and older adults mark a significant public health milestone.

Drugs 173

Drugs Therapies Treatment Virus 173

Drug Discovery World

OCTOBER 4, 2022

There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . The global lab automation market for drug discovery is expected to grow by a CAGR of 5% between 2021 – 2026, according to a report by Mordor Intelligence. . Cell and gene therapies.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Vial

MARCH 1, 2024

By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

The Pharma Data

MARCH 31, 2022

650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. The transaction has been led by Morgan Stanley and Natixis CIB as Global Coordinators & Sustainability-Linked Structuring Advisors and, Barclays, MUFG and RBC Capital Markets, all as Joint Active Bookrunners.

Government 52

Government Treatment Vaccine Disease 52

Policy Prescription

MARCH 26, 2021

Within the context of the global pandemic and a coming battle in Congress about the high cost of prescription drugs, Patients for Affordable Drugs founder David Mitchell tactfully presents the roadmap of Covid vaccine development to prevent people from buying into Big Pharma’s scare tactic. 3) were implemented.

Drugs 52

Drugs Government Vaccine Pharmaceuticals 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. state pharmaceutical assistance programs). had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Pharmacy Drugs Licensing 105